UNSPSC 51283903: Phthalylsulfathiazole

This classification denotes a sulfonamide anti-infective agent with the molecular formula C17H13N3O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6875L5852V, chemically known as sulfanilamide, n(sup 4)-(o-carboxybenzoyl)-n-2-thiazolyl- but generally known as phthalylsulfathiazole, which bears US NIH Compound Identifier 4806. European Medicines Agency schedules Phthalylsulfathiazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09799MIG.

UNSPSC 51283903 Phthalylsulfathiazole is a Commodity code that nominally covers a specific antimicrobial pharmaceutical compound, but recent state and local procurement activity under this code shows little alignment with that narrow definition. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets — neither matching the coded pharmaceutical. Separately, Seminole County, Florida issued an IFB in June 2026 for Naloxone and Safe Drug Deactivation Systems, also unrelated to phthalylsulfathiazole. State and local purchasing offices appear to use this code broadly or incorrectly across diverse pharmaceutical procurement rather than restricting it to the specific compound. Issuing bodies soliciting under this code include state health departments and county health authorities pursuing pharmaceutical supply contracts through cooperative purchasing vehicles and competitive bidding.

Activity concentrating in Illinois and Florida, though the sample is sparse. The Illinois award demonstrates the use of consortium piggyback contracts (MMCAP Infuse) for multi-year pharmaceutical supply with 12-month initial terms and renewal options. The Seminole County procurement (response deadline July 26, 2023, posted June 30, 2026) required quarterly deliveries, E-Verify compliance, and potential FEMA funding with associated federal compliance obligations. Neither recent opportunity shows set-aside designations for disadvantaged enterprises or domestic product preferences. The code shows minimal recent relevant activity; if pursuing opportunities in pharmaceutical supply to state health departments or county health authorities, monitor cooperative purchasing consortia and county health procurement boards rather than relying on this code's nominal classification.